MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Navigating Open Science in Canada with the Canadian Open Parkinson Network

M. Cressatti, C. Normandeau, C. Degroot, I. Kathol, A. Stoessl, M. Mckeown, J. Miyasaki, R. Camicioli, D. Grimes, L. Kalia, A. Strafella, P. Macdonald, N. Dupré, E. Fon, O. Monchi (Calgary, Canada)

Meeting: 2023 International Congress

Abstract Number: 1946

Keywords: Parkinson’s, Parkinsonism

Category: Other

Objective: The Canadian Open Parkinson Network (C-OPN) is a pan-Canadian initiative that bridges people, data and resources to accelerate new discoveries in the field of Parkinsonisms.

Background: C-OPN aims to operate under the principles of Open Science by facilitating rapid sharing of data and samples with Canadian and international investigators. Ten of Canada’s top universities and movement disorders research centres from British Columbia, Alberta, Ontario and Quebec are part of C-OPN.

Method: C-OPN recruits participants with Parkinson’s disease (PD), Parkinson Plus Syndromes (PPS) as well as healthy controls. The C-OPN database collects de-identified clinical data with comprehensive information about each participant’s demographics, along with details of their symptoms and medications; assessments results (MoCA, MDS-UPDRS); and a biobank with biomaterials extracted from blood samples (DNA, peripheral blood mononuclear cells [PBMC] and serum). These resources are made available to C-OPN members (clinicians, scientists, trainees) and industry partners via a digital platforms (REDCap and LORIS).

Results: To date, the project has enrolled over 1280 participants across Canada, including PD, PPS and healthy control groups. C-OPN participants exhibit a male:female ratio of 1.3:1, 91% report Caucasian or French-Canadian ethnicity and 74% report more than 12 years of education. The average age at diagnosis 60 years for PD and 69 years for PPS. While data sharing across provincial and international lines has limitations, the C-OPN model has overcome these challenges and 15 research projects and counting have utilized C-OPN resources to date.

Conclusion: Together, C-OPN seeks to support cutting-edge, multi-disciplinary and multi-site PD-related research studies across Canada and around the world. This project has been made possible by Parkinson Canada and Brain Canada through the Canada Brain Research Fund, with the financial support of Health Canada.

To cite this abstract in AMA style:

M. Cressatti, C. Normandeau, C. Degroot, I. Kathol, A. Stoessl, M. Mckeown, J. Miyasaki, R. Camicioli, D. Grimes, L. Kalia, A. Strafella, P. Macdonald, N. Dupré, E. Fon, O. Monchi. Navigating Open Science in Canada with the Canadian Open Parkinson Network [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/navigating-open-science-in-canada-with-the-canadian-open-parkinson-network/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/navigating-open-science-in-canada-with-the-canadian-open-parkinson-network/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley